Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer
Taruba Rais, Amna Shakeel, Laiba Naseem, Nathalie Nasser, Minahil Aamir · 2024
Read Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer by Taruba Rais, Amna Shakeel, Laiba Naseem, Nathalie Nasser, Minahil Aamir (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11623886.txt.
Description
Taruba Rais and four colleagues review repotrectinib, a newly approved drug for advanced non-small cell lung cancer, in a 2024 paper. This cancer type causes most lung cancer deaths, and tumors driven by ROS1 or NTRK gene changes need targeted options. Repotrectinib blocks the faulty kinases behind those changes. In the TRIDENT-1 trial it delivered strong response rates and lasting benefit, including inside the brain, for both new and previously treated patients. Its side effects looked manageable, and the authors present it as a meaningful addition for these tumor types.
Catalog record
| CREATOR | Taruba Rais, Amna Shakeel, Laiba Naseem, Nathalie Nasser, Minahil Aamir |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |